|1.||Morris, Sidney M: 22 articles (11/2015 - 07/2003)|
|2.||Caldwell, Ruth B: 16 articles (03/2015 - 08/2009)|
|3.||Cederbaum, Stephen D: 14 articles (10/2014 - 07/2002)|
|4.||Grasemann, Hartmut: 13 articles (05/2015 - 12/2005)|
|5.||Rodriguez, Paulo C: 13 articles (01/2015 - 06/2002)|
|6.||Munder, Markus: 13 articles (12/2014 - 09/2006)|
|7.||Barańczyk-Kuźma, Anna: 13 articles (09/2014 - 06/2002)|
|8.||Christianson, David W: 13 articles (07/2014 - 07/2003)|
|9.||Morris, Claudia R: 13 articles (01/2013 - 07/2003)|
|10.||Caldwell, R William: 12 articles (03/2015 - 02/2010)|
09/01/1984 - "PEG-arginase was effective in prolonging the survival times of mice injected with the Taper liver tumor, whereas unmodified arginase was ineffective. "
08/01/2014 - "We hypothesized that tumor myeloid cells inhibit the adaptive immune response after radiation therapy through expression of the enzyme arginase I. Using a myeloid cell-specific deletion of arginase I in mice, we demonstrate an improved tumor control after radiation therapy. "
01/01/2015 - "Recent studies have also shed light on the mechanism of tumor cell death with Arg deprivation, with arginase and pegylated Arg deiminase. "
07/15/2013 - "In the present study, we found that Gr-1(+)CD115(+) monocytes in tumor-bearing mice exhibited M2 characteristics with significantly lower expression of iNOS and higher expression of Arginase I. Immunofluorescence staining showed that Gr-1(+)CD115(+) monocytes in tumor sites from LPS-injected mice had a higher expression of iNOS. "
02/01/2013 - "The current study evaluated safety, pharmacokinetics (PK)/ pharmacodynamics (PD) parameters, and potential anti-tumor activity of pegylated recombinant human arginase 1 (peg-rhArg1) in advanced HCC patients. "
12/01/2012 - "This study was to investigate whether or not there is a crosstalk between arginase and S6K1 in endothelial inflammation and aging in senescent human umbilical vein endothelial cells and in aging mouse models. "
05/27/2010 - "The most potent inhibitor identified in this study, 2-(S)-amino-5-(2-aminoimidazol-1-yl)pentanoic acid (A1P, 10), binds to human arginase I with K(d) = 2 microM and significantly attenuates airways hyperresponsiveness in a murine model of allergic airways inflammation. "
02/15/2010 - "Studies in models of retinopathy show that increases in oxidative stress and signs of vascular inflammation are correlated with increases in arginase activity and arginase 1 expression and that decreasing arginase expression or inhibiting its activity blocks these effects. "
02/27/2007 - "The aim of the present study was to characterize the time course of arginase pathway abnormalities in SHR and to explore the contributing role of hemodynamics and inflammation. "
11/06/2015 - "To test the hypothesis that FoxO4 promotes early post-MI inflammation via endothelial arginase 1 (Arg1). "
|3.||Asthma (Bronchial Asthma)
12/01/2005 - "Increases in both arginase transcript and enzyme activity were significantly greater in OVA-induced asthma compared to TMA-induced asthma. "
01/01/2011 - "This study demonstrates that arginase is upregulated following environmental exposures in murine models of asthma, and contributes to the pollution-induced exacerbation of airways responsiveness. "
09/15/2008 - "This is the first in vivo study indicating that arginase inhibitors may have therapeutic potential in allergic asthma."
01/01/2006 - "A recent microarray study implicated arginase I (ARG1) and arginase II (ARG2) in mouse allergic asthma models and human asthma. "
10/01/2005 - "These findings, in conjunction with human studies showing a role for arginase in acute asthma, open a new horizon for the therapeutic potential of drugs targeting the arginase pathway in asthma."
|4.||Hepatocellular Carcinoma (Hepatoma)
04/01/2015 - "This study was designed to evaluate the efficacy, safety profile, pharmacokinetics, pharmacodynamics and quality of life of pegylated recombinant human arginase 1 (Peg-rhAgr1) in patients with advanced hepatocellular carcinoma (HCC). "
04/01/2015 - "Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma."
02/01/2013 - "A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma."
01/01/2013 - "Clinicopathological and prognostic implications of arginase expression in hepatocellular carcinoma."
05/08/2009 - "Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest."
09/21/1907 - "This increase corresponds to the degree of necrosis and attendant circulatory disturbance and indicates that in necrosis as opposed to degeneration (Wakeman) arginin is not split up by arginase. "
06/01/1998 - "The protective effects of arginase in these apoptotic paradigms, in contrast to previous studies on excitotoxic neuronal necrosis, are independent of nitric oxide synthase inhibition. "
08/01/2004 - "- We have: (i) characterised arginase pathway in terms of activity, isoform type and gene expression in a primary human umbilical vein endothelial cells (HUVEC) line; (ii) evaluated arginase functional role in cell proliferation with the aid of l-norvaline, an arginase inhibitor and (iii) determined the effects of tumour necrosis factor-alpha and endotoxin on arginase pathway. "
01/01/1994 - "The determination of arginase by a simple procedure such as the PNPG method, in conjunction with AST or ALT assay, may be of value in assessing the stage of liver necrosis."
04/01/1963 - "Comparative studies on plasma arginase and transaminases in hepatic necrosis."
|2.||Nitric Oxide (Nitrogen Monoxide)
|3.||Nitric Oxide Synthase (NO Synthase)
|8.||Messenger RNA (mRNA)